7
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Predicting Survival of Patients with Nonmetastatic Breast Cancer Based on Fibrinogen-to-Albumin Ratio and Lymphocyte-to-Monocyte Ratio: A Nomogram-Based Assessment

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Parameters of systemic inflammation have received attention as prognostic surrogates in various malignant tumors. Fibrinogen-to-albumin ratio (FAR) and lymphocyte-to-monocyte ratio (LMR) correlate with tumor growth and dissemination. We aimed to bring the combination of FAR and LMR (FAR-LMR) together to establish novel nomograms for survival and recurrence in nonmetastatic breast cancer patients. Methods: We retrospectively recruited 461 female patients with nonmetastatic breast cancer from January 2011 to December 2013 in our hospital and randomly assigned them into the training cohort ( N = 318) and the validation cohort ( N = 143). The potential predictive factors for overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed by Cox proportional hazards models and log-rank test. Results: Elevated FAR was associated with poor OS ( p < 0.001) and DMFS ( p = 0.02), whereas increased LMR was associated with satisfactory OS ( p = 0.01) and LRFS ( p = 0.01). High FAR combined with low LMR was associated with less favorable OS ( p = 0.001), LRFS ( p = 0.005), and DMFS ( p = 0.003) Based on multivariate analysis, FAR-LMR, tumor size, lymph node metastasis, age, and pathologic status contributed to prognostic nomograms of OS, DMFS, and LRFS. Nomograms presented exceptional performance for 3-, 5-, and 8-year OS, DMFS, and LRFS prediction compared with clinical TNM stage. The C-index was significantly higher than that of TNM stage, either of FAR or LMR (3-year: 0.709 vs. 0.621 vs. 0.544 vs. 0.641, 5-year: 0.761 vs. 0.597 vs. 0.605 vs. 0.677, 8-year: 0.84 vs. 0.62 vs. 0.539 vs. 0.623). Conclusions: We developed and validated a convenient predictive model for the survival outcomes of patients with nonmetastatic breast cancer. The nomograms can be utilized as auxiliary tools to provide prognostic information.

          Related collections

          Author and article information

          Journal
          BRC
          BRC
          10.1159/issn.1661-3791
          Breast Care
          Breast Care
          S. Karger AG
          1661-3791
          1661-3805
          2023
          October 2023
          26 July 2023
          : 18
          : 5
          : 374-389
          Affiliations
          [_a] aState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
          [_b] bDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China
          [_c] cDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
          Author notes
          *Ling Guo, guoling@sysucc.org.cn, Huan-Xin Lin, linhx@sysucc.org.cn
          Article
          531939 Breast Care 2023;18:374–388
          10.1159/000531939
          37901049
          9fcc2a69-ab5b-4fcf-80a9-2c1daf499121
          © 2023 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 28 February 2022
          : 30 May 2023
          Page count
          Figures: 6, Tables: 3, Pages: 15
          Funding
          The work was supported by the Natural Science Foundation of Guangdong Province (2017A030313617) and National Natural Science Foundation of China (81773103).
          Categories
          Research Article

          Medicine
          Lymphocyte‐to‐monocyte ratio,Nomogram,Prognosis,Breast cancer,Fibrinogen‐to‐albumin ratio

          Comments

          Comment on this article